

Twitter Thread by [Sajal Kapoor](#)



Sajal Kapoor

[@unseenvalue](#)



Research in CDMO/APIs is never a slam dunk. It may take ages to yield results. CEP filings can be lumpy as a result. As I wrote last year (link below), Hikal has been consistently sacrificing operating profits for a sustainable future. Best is ahead ■ ■

<https://t.co/hltmOud8Pm>

[#Hikal](#) has stepped up R&D in recent years. Next few years (capex & launches) should yield superior earnings. Wish them all the luck \U0001f44d

D: invested and biased view for sure, but it was below 1x price to sales vs 12x price to sales for many chemicals and generic players. No reco!! pic.twitter.com/aqPUKbziHK

— Sajal Kapoor ([@unseenvalue](#)) [September 26, 2020](#)